Titles
- Biological product deviation reporting for blood and plasma establishments1
- Biologics in perspective: the case for generic biologic drugs1
- Biomedical research: information on federal contributions to remdesivir : report to Congressional addressees1
- Bipartisan Rx for America's health care: a practical path to reform1
- Bipartisan approaches to tackling health care costs at the state level1
- Bipartisan solutions to improve the availability of long-term care1
- Birth defects and developmental disabilities: the search for causes and cures1
- Birth defects tracking and prevention: too many states are not making the grade1
- Bispecific antibody development programs1
- Black Lung Benefits Program: oversight is needed to address trust fund solvency strained by bankruptcies : testimony before the Committee on Education and Labor, Subcommittee on Workforce Protections, House of Representatives1
- Black Lung benefits program: continued inaction on coal operator self-insurance increases financial risk to trust fund : testimony before the Committee on Education and Labor, Subcommittee on Workforce Protections, House of Representatives1
- Black and African American adults’ perspectives on discrimination and unfair judgment in health care1
- Black patients are more likely than white patients to be in hospitals with worse patient safety conditions1
- Blood glucose monitoring test systems for prescription point-of-care use: guidance for industry and Food and Drug Administration staff1
- Blood transfusion events--lessons learned from a complex process1
- Blueprint for a healthier America: modernizing the federal public health system to focus on prevention and preparedness1
- Blueprint for a healthier America: policy priorities for the next Administration and Congress1
- Board service: from in perpetuity to term limits1
- Bolstered by recovery legislation, the health insurance safety net prevented a rise in uninsurance between 2019 and 20211
- Bone anchors: premarket notification (510(k)) submissions : guidance for industry and Food and Drug Administration staff1